Skip to main content

Table 4 Demographic and laboratory parameters stratified to risk category based on hsCRP levels

From: Markers of inflammation and coagulation indicate a prothrombotic state in HIV-infected patients with long-term use of antiretroviral therapy with or without abacavir

  Low risk category
(hsCRP < 1 mg/L)
Average risk category
(hsCRP 1-3 mg/L)
High risk category
(hsCRP >3 mg/L)
Number of patients 28 24 27
Age (years) 47.8 (± 10.2) 48.4 (± 11.6) 48.2 (± 9.1)
Duration of cART use (months) 76 (25-125) 116 (42-124) 111 (26-127)
CD4 cell count (cells/mm3) 390 (300-765) 460 (340-805) 500 (288-633)
HIV viral load <40 copies/ml (%) 24 (86) 21 (88) 22 (81)
Total cholesterol (mmol/L) 4.9 (± 1.0) 5.7 (± 0.9) 5.1 (± 0.8)
Triglycerides (mmol/L) 2.2 (± 1.9) 2.7 (± 2.0) 2.0 (± 1.4)
Non-fasting glucose (mmol/L) 5.9 (± 1.1) 5.9 (± 1.1) 6.1 (± 1.6)
Patients on ABC (%) 9 (32) 7 (29) 11 (41)
aPTT (sec) 31.5 (± 3.3) 32.2 (± 3.1) 30.5 (± 3.2)
PT (sec) 11.8 (± 0.9) 11.7 (± 0.6) 11.5 (± 0.8)
Fibrinogen (g/L) 2.4 (2.1-2.6) 2.8 (2.3-3.2)* 3.5 (2.8-4.1)*
FVIII (%) 115 (102-145) 122 (105-172) 122 (100-158)
vWF (%) 124 (92-160) 123 (101-177) 114 (98-188)
D-dimer (mg/L) 0.2 (0.2-0.3) 0.2 (0.2-0.3) 0.3 (0.2-0.5)*
F1+2 (pmol/L) 175 (151-229) 210 (163-269) 219 (197-305)*
PC (%) 114 (± 25.7) 111 (± 20.6) 120 (± 20.9)
PS total (%) 96 (± 18.7) 104 (± 14.5) 105 (± 20.8)
PS free (%) 87 (± 16.8) 93 (± 24.8) 82 (± 26.0)
ETP (nM.min) 1663 (± 274) 1803 (± 237)* 1913 (± 336)*
ETP peak (nM) 371 (328-401) 371 (341-407) 386 (364-417)
APCsr 2.9 (2.1-3.7) 2.0 (1.7-2.9)* 2.6 (1.6-4.4)
VEGF (pg/ml) 30 (24-42) 30 (26-52) 37 (27-53)
IL-6 (pg/ml) 1.0 (-) 1.0 (-) 1.0 (-)
  1. hsCRP = high-sensitivity C-reactive protein; fVIII = factor; vWF = von Willebrand factor; F1+2 = prothrombin fragment 1+2; PC = protein C; PS = protein S; ETP = endogenous thrombin potential; APCsr = activated protein C sensitivity ratio; VEGF = vascular endothelial growth factor
  2. *p < 0.05 (after Bonferroni correction for multiple testing)